The deadly outbreak of Ebola in West Africa is pushing related vaccine and drug development efforts from first gear into overdrive. Today it's J&J's turn to step up, teaming with the Danish biotech Bavarian Nordic to pair up vaccine components into a new jab with the help of the National Institute of Allergy and Infectious Diseases. And the pharma giant says it can start testing the new combination vaccine in a rushed clinical trial slated to start in early 2015.
Hot on the heels of its $805 million development deal with Infinity, AbbVie Pharmaceuticals has followed up today with a plan to partner with Google's closely watched biotech upstart Calico on a new research operation that will cost up to $1.5 billion to get started.
BioTime is entering into a partnership with the University of Wisconsin and Belgium's Louvain University to develop the company's hydrogel-based treatment for vocal fold scarring.
AbbVie has agreed to hand over $275 million upfront to Infinity Pharmaceuticals in exchange for rights to develop and commercialize duvelisib, its oral PI3k-delta/gamma inhibitor for blood cancers. And the blockbuster-size deal for Infinity's lead program comes with $530 million in potential milestones.
German CRO Cenix BioScience has signed a deal with a BASF subsidiary to help ferret out new biomarkers, focusing on the growing field of metabolomics.
Cancer Research UK has enlisted contract drugmaker Onyx Scientific to pitch in on some of its early research projects, handling development and manufacturing for clinical trials.
Drug developer Catalent is teaming up with biomarker outfit Minomic International to get a new prostate cancer treatment into the clinic, tapping its expertise in crafting targeted oncology treatments.
Just over a month after striking an immunotherapy pact with AstraZeneca, New Jersey biotech Advaxis is back with another Big Pharma agreement. This time, the company will be teaming up with Merck to test its cancer vaccine, ADXS-PSA, in combination with the latter's checkpoint inhibitor pembrolizumab.
Advanced Catheter Therapies' venture capital funding round has been oversubscribed, reflecting investor interest in the company's Occlusion Perfusion Catheter for localized drug delivery in the peripheral vasculature.
Merck and Pfizer have struck a deal to add the immuno-oncology superstar pembrolizumab to Xalkori for ALK-positive cases of advanced non-small cell lung cancer.